Understanding the Trial Results
The trial tested a medication called dapagliflozin for people with metabolic dysfunction-associated steatohepatitis (MASH). Here’s what the results mean:
What Worked?
- 53% of participants taking dapagliflozin showed improvement in MASH without worsening liver fibrosis.
- 23% of those on dapagliflozin had complete resolution of MASH without worsening fibrosis.
- 45% experienced improvement in fibrosis without worsening MASH.
What Didn’t Work?
- The placebo group had lower rates of improvement and resolution compared to the dapagliflozin group.
How Does This Help Patients and Clinics?
This medication can significantly improve liver health in patients with MASH, offering a new treatment option for those struggling with this condition. Clinics can provide better care by incorporating dapagliflozin into treatment plans.
Real-World Opportunities
- Doctors can start prescribing dapagliflozin for eligible patients with MASH.
- Hospitals can develop programs to monitor patients’ liver health while on this medication.
Measurable Outcomes to Track
- Improvement in non-alcoholic fatty liver disease activity score (NAS).
- Rates of MASH resolution and fibrosis improvement.
- Patient-reported side effects and treatment adherence.
AI Tools to Consider
Clinics can explore AI tools for tracking patient data and outcomes, which can help in monitoring liver health and treatment effectiveness.
Step-by-Step Plan for Clinics
- Start by educating staff about the benefits of dapagliflozin for MASH.
- Identify patients who may benefit from this treatment.
- Begin prescribing dapagliflozin to a small group of patients.
- Monitor their progress and gather data on outcomes.
- Gradually expand the program based on initial results and feedback.
